12 completed, 2 active not recruiting, 2 enrolling by invitation, 1 recruiting. 7 Phase 3, 5 Phase 1, 3 Phase 4, 2 Phase 2, 1 Not applicable.
Follow ubrogepant: new trials by email Literature Review of ubrogepant trials Research Report on ubrogepant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants Ubrogepant - Healthy Volunteer | Phase 1 | Active not recruiting | AbbVie | 52 | 2026-07-14 | 2026-10-13 |
| A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine Ubrogepant, Lu AG09222, Placebo - Migraine | Phase 1 | Completed | H. Lundbeck A/S | 43 | 2024-09-13 | 2025-10-14 |
| Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine Ubrogepant, Placebo for Ubrogepant - Migraine | Phase 3 | Active not recruiting | AbbVie | 496 | 2024-09-10 | 2026-08-14 |
| Migraine Medication Effects on Urinary Symptoms Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 | |
| Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers Atogepant, Ubrogepant - Healthy Volunteers | Phase 1 | Completed | AbbVie | 24 | 2023-07-11 | 2024-03-12 |
| Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy] - Headache, Migraine | Phase 4 | Unknown | Chicago Headache Center & Research Institute | 164 | 2022-09-06 | 2024-08-20 |
| Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine Almotriptan 12.5 Mg Oral Tablet, Ubrogepant 50Mg Tab - Migraine With Aura, Migraine Without Aura | Phase 4 | Terminated | Messoud Ashina, MD | 8 | 2022-06-30 | 2025-05-31 |
| Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin Sumatriptan, Ubrogepant - Migraine | Not applicable | Completed | Universitaire Ziekenhuizen KU Leuven | 20 | 2022-03-15 | 2023-03-28 |
| Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine Atogepant, Ubrogepant - Episodic Migraine | Phase 4 | Completed | AbbVie | 263 | 2022-03-07 | 2024-10-08 |
| Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) Ubrogepant - Migraine | Phase 3 | Enrolling by invitation | AbbVie | 1200 | 2022-01-14 | 2025-07-20 |
| Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Ubrogepant, Placebo-Matching Ubrogepant - Migraine | Phase 3 | Recruiting | AbbVie | 1059 | 2022-01-13 | 2026-09-14 |
| Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine Atogepant, Ubrogepant - Migraine | Phase 1 | Completed | AbbVie | 26 | 2021-03-17 | 2022-06-16 |
| Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants Ubrogepant 100 mg, Placebo - Migraine | Phase 3 | Completed | AbbVie | 518 | 2020-08-21 | 2023-05-31 |
| Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Ubrogepant, Erenumab, Galcanezumab - Migraine | Phase 1 | Completed | Allergan | 40 | 2019-09-26 | 2021-03-10 |
| An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant, Usual Care - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1254 | 2016-09-13 | 2019-08-28 |
| Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1686 | 2016-08-26 | 2019-03-19 |
| Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1672 | 2016-07-22 | 2019-01-03 |
| A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007) MK-1602, Placebo, Rescue medication - Migraine | Phase 2 | Completed | Allergan | 195 | 2012-08-01 | 2016-12-09 |
| A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) MK-1602, Placebo-matching MK-1602, Rescue medication - Migraine | Phase 2 | Completed | Allergan | 834 | 2012-07-01 | 2019-01-08 |
Migraine Disorders (15) · Cystitis, Interstitial (1) · Migraine with Aura (1) · Migraine without Aura (1) · Urinary Bladder, Overactive (1)
AbbVie (8) · Allergan (6) · Chicago Headache Center & Research Institute (1) · H. Lundbeck A/S (1) · Messoud Ashina, MD (1) · The Cleveland Clinic (1) · Universitaire Ziekenhuizen KU Leuven (1)
United States (15) · Puerto Rico (3) · Belgium (1) · Denmark (1)
Adele Thorpe (3) · Bradley Torphy, MD (1) · Howard B Goldman, MD (1) · Messoud Ashina, Prof. (1) · Ramesh Boinpally (1)
PMID 39982105, PMID 34874514, PMID 33241721, PMID 33608814, PMID 33874756, PMID 35468729, PMID 36125279, PMID 31742631, PMID 31800988, PMID 35977836, PMID 37979595, PMID 39197113, PMID 39399572, PMID 39569702, PMID 40391560, PMID 40455369, PMID 42012062